Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thunnissen, E, Lissenberg-Witte, BI, van den Heuvel, MM, Monkhorst, K, Skov, BG, Sørensen, JB, Mellemgaard, A, Dingemans, AMC, Speel, EJM, de Langen, AJ, Hashemi, SMS, Bahce, I, van der Drift, MA, Looijen-Salamon, MG, Gosney, J, Postmus, PE, Samii, SMS, Duplaquet, F, Weynand, B, Durando, X, Penault-Llorca, F, Finn, S, Grady, AO, Oz, B, Akyurek, N, Buettner, R, Wolf, J, Bubendorf, L, Duin, S, Marondel, I, Heukamp, LC, Timens, W, Schuuring, EMD, Pauwels, P & Smit, EF 2019, 'ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib' Lung cancer, vol. 138, pp. 13-18. https://doi.org/10.1016/j.lungcan.2019.09.023

APA

CBE

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF. 2019. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung cancer. 138:13-18. https://doi.org/10.1016/j.lungcan.2019.09.023

MLA

Vancouver

Author

Thunnissen, E ; Lissenberg-Witte, B I ; van den Heuvel, M M ; Monkhorst, K ; Skov, B G ; Sørensen, J B ; Mellemgaard, A ; Dingemans, A M C ; Speel, E J M ; de Langen, A J ; Hashemi, S M S ; Bahce, I ; van der Drift, M A ; Looijen-Salamon, M G ; Gosney, J ; Postmus, P E ; Samii, S M S ; Duplaquet, F ; Weynand, B ; Durando, X ; Penault-Llorca, F ; Finn, S ; Grady, A O ; Oz, B ; Akyurek, N ; Buettner, R ; Wolf, J ; Bubendorf, L ; Duin, S ; Marondel, I ; Heukamp, L C ; Timens, W ; Schuuring, E M D ; Pauwels, P ; Smit, E F. / ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. In: Lung cancer. 2019 ; Vol. 138. pp. 13-18.

Bibtex

@article{41b8e52ac9a74fd99fae7e00d051e191,
title = "ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib",
abstract = "OBJECTIVE: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH+). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC)+). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.MATERIALS AND METHODS: In this European prospective multicenter research study patients with Stage IV ALK IHC + NSCLC treated with crizotinib were enrolled. Tumor slides were validated centrally for ALK IHC and ALK FISH.RESULTS: Registration of 3523 ALK IHC tests revealed a prevalence of 2.7{\%} (n = 94) ALK IHC + cases. Local ALK FISH analysis resulted in 48 concordant (ALK IHC+/FISH+) and 16 discordant (ALK IHC+/FISH-) cases. Central validation revealed 37 concordant and 7 discordant cases, 5 of which had follow-up. Validation was hampered by limited amount of tissue in biopsy samples. The PFS at 1 year for ALK concordant and discordant was 58{\%} and 20{\%}, respectively (HR = 2.4; 95{\%} CI: 0.78-7.3; p = 0.11). Overall survival was significantly better for concordant cases than discordant cases after central validation (HR=4.5; 95{\%} CI= 1.2-15.9; p=0.010.CONCLUSION: ALK IHC + FISH- NSCLC is infrequent and associated with a worse outcome on personalized treatment. A suitable predictive testing strategy may be to screen first with IHC and then confirm with FISH instead of considering ALK IHC equivalent to ALK FISH according to the current guidelines.",
author = "E Thunnissen and Lissenberg-Witte, {B I} and {van den Heuvel}, {M M} and K Monkhorst and Skov, {B G} and S{\o}rensen, {J B} and A Mellemgaard and Dingemans, {A M C} and Speel, {E J M} and {de Langen}, {A J} and Hashemi, {S M S} and I Bahce and {van der Drift}, {M A} and Looijen-Salamon, {M G} and J Gosney and Postmus, {P E} and Samii, {S M S} and F Duplaquet and B Weynand and X Durando and F Penault-Llorca and S Finn and Grady, {A O} and B Oz and N Akyurek and R Buettner and J Wolf and L Bubendorf and S Duin and I Marondel and Heukamp, {L C} and W Timens and Schuuring, {E M D} and P Pauwels and Smit, {E F}",
note = "Copyright {\circledC} 2019 Elsevier B.V. All rights reserved.",
year = "2019",
month = "12",
doi = "10.1016/j.lungcan.2019.09.023",
language = "English",
volume = "138",
pages = "13--18",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

AU - Thunnissen, E

AU - Lissenberg-Witte, B I

AU - van den Heuvel, M M

AU - Monkhorst, K

AU - Skov, B G

AU - Sørensen, J B

AU - Mellemgaard, A

AU - Dingemans, A M C

AU - Speel, E J M

AU - de Langen, A J

AU - Hashemi, S M S

AU - Bahce, I

AU - van der Drift, M A

AU - Looijen-Salamon, M G

AU - Gosney, J

AU - Postmus, P E

AU - Samii, S M S

AU - Duplaquet, F

AU - Weynand, B

AU - Durando, X

AU - Penault-Llorca, F

AU - Finn, S

AU - Grady, A O

AU - Oz, B

AU - Akyurek, N

AU - Buettner, R

AU - Wolf, J

AU - Bubendorf, L

AU - Duin, S

AU - Marondel, I

AU - Heukamp, L C

AU - Timens, W

AU - Schuuring, E M D

AU - Pauwels, P

AU - Smit, E F

N1 - Copyright © 2019 Elsevier B.V. All rights reserved.

PY - 2019/12

Y1 - 2019/12

N2 - OBJECTIVE: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH+). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC)+). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.MATERIALS AND METHODS: In this European prospective multicenter research study patients with Stage IV ALK IHC + NSCLC treated with crizotinib were enrolled. Tumor slides were validated centrally for ALK IHC and ALK FISH.RESULTS: Registration of 3523 ALK IHC tests revealed a prevalence of 2.7% (n = 94) ALK IHC + cases. Local ALK FISH analysis resulted in 48 concordant (ALK IHC+/FISH+) and 16 discordant (ALK IHC+/FISH-) cases. Central validation revealed 37 concordant and 7 discordant cases, 5 of which had follow-up. Validation was hampered by limited amount of tissue in biopsy samples. The PFS at 1 year for ALK concordant and discordant was 58% and 20%, respectively (HR = 2.4; 95% CI: 0.78-7.3; p = 0.11). Overall survival was significantly better for concordant cases than discordant cases after central validation (HR=4.5; 95% CI= 1.2-15.9; p=0.010.CONCLUSION: ALK IHC + FISH- NSCLC is infrequent and associated with a worse outcome on personalized treatment. A suitable predictive testing strategy may be to screen first with IHC and then confirm with FISH instead of considering ALK IHC equivalent to ALK FISH according to the current guidelines.

AB - OBJECTIVE: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH+). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC)+). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.MATERIALS AND METHODS: In this European prospective multicenter research study patients with Stage IV ALK IHC + NSCLC treated with crizotinib were enrolled. Tumor slides were validated centrally for ALK IHC and ALK FISH.RESULTS: Registration of 3523 ALK IHC tests revealed a prevalence of 2.7% (n = 94) ALK IHC + cases. Local ALK FISH analysis resulted in 48 concordant (ALK IHC+/FISH+) and 16 discordant (ALK IHC+/FISH-) cases. Central validation revealed 37 concordant and 7 discordant cases, 5 of which had follow-up. Validation was hampered by limited amount of tissue in biopsy samples. The PFS at 1 year for ALK concordant and discordant was 58% and 20%, respectively (HR = 2.4; 95% CI: 0.78-7.3; p = 0.11). Overall survival was significantly better for concordant cases than discordant cases after central validation (HR=4.5; 95% CI= 1.2-15.9; p=0.010.CONCLUSION: ALK IHC + FISH- NSCLC is infrequent and associated with a worse outcome on personalized treatment. A suitable predictive testing strategy may be to screen first with IHC and then confirm with FISH instead of considering ALK IHC equivalent to ALK FISH according to the current guidelines.

U2 - 10.1016/j.lungcan.2019.09.023

DO - 10.1016/j.lungcan.2019.09.023

M3 - Journal article

VL - 138

SP - 13

EP - 18

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -

ID: 59002969